Solvonis Therapeutics (SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (“CNS”) disorders, announced the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.
Solvonis Therapeutics (SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (“CNS”) disorders, announced the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.